A randomized controlled trial was undertaken to compare clinical and parasitological efficacy of a combined oral therapy with spiramycin-metronidazole (Stomorgyl® = St) with N-methyl-glucamine antimoniate & allopurinol treatment (conventional therapy = CT) in dogs spontaneously infected with L. infantum. Thirteen dogs were treated with spiramycin (150.000 IU/Kg) and metronidazole (25 mg/Kg) SID, PO for 90 days and 14 dogs with N-methyl-glucamine antimoniate (50-100 mg/Kg BID SC) and allopurinol (20 mg/Kg BID PO) for 90 days. All the animals have been followed up every other week during therapy and after then monthly for 4 months, undergoing to clinical scoring, blood cell count, general biochemical profile and urine analysis, serum protein electrophoresis, PCR (blood and lymph-node) and anti-Leishmania IFAT. Dogs completing therapy: 12/13 St; 10/14 CT. Stopping therapy because of side-effects: 1/13 St (pemphigus foliaceus); 4/14 CT (2 local reaction at injection sites, 2 worsening of hepatitis, dermatitis). Clinical cure: 7/13 St; 6/14 CT. Improved clinical picture: 4/13 St; 4/14 CT. Unchanged clinical picture: 1/13 St (the dog was then treated with CT but died in five days); 2/14 CT. Worsened clinical picture: 1/13 St (the dog was then treated with CT with clinical cure); 2/14 CT (both were treated with St therapy with clinical cure). Clinical recurrence: 2 dogs treated with St and nobody of the CT group. Dogs seronegative at the end of the trial: 2/13 St; 0/14 CT. PCR: with both treatments negative and positive results alternated during and after therapy.

EFFICACY OF METRONIDAZOLE-SPIRAMYCIN COMBINED THERAPY IN THE TREATMENT OF CANINE LEISHMANIASIS

Britti D;
2001-01-01

Abstract

A randomized controlled trial was undertaken to compare clinical and parasitological efficacy of a combined oral therapy with spiramycin-metronidazole (Stomorgyl® = St) with N-methyl-glucamine antimoniate & allopurinol treatment (conventional therapy = CT) in dogs spontaneously infected with L. infantum. Thirteen dogs were treated with spiramycin (150.000 IU/Kg) and metronidazole (25 mg/Kg) SID, PO for 90 days and 14 dogs with N-methyl-glucamine antimoniate (50-100 mg/Kg BID SC) and allopurinol (20 mg/Kg BID PO) for 90 days. All the animals have been followed up every other week during therapy and after then monthly for 4 months, undergoing to clinical scoring, blood cell count, general biochemical profile and urine analysis, serum protein electrophoresis, PCR (blood and lymph-node) and anti-Leishmania IFAT. Dogs completing therapy: 12/13 St; 10/14 CT. Stopping therapy because of side-effects: 1/13 St (pemphigus foliaceus); 4/14 CT (2 local reaction at injection sites, 2 worsening of hepatitis, dermatitis). Clinical cure: 7/13 St; 6/14 CT. Improved clinical picture: 4/13 St; 4/14 CT. Unchanged clinical picture: 1/13 St (the dog was then treated with CT but died in five days); 2/14 CT. Worsened clinical picture: 1/13 St (the dog was then treated with CT with clinical cure); 2/14 CT (both were treated with St therapy with clinical cure). Clinical recurrence: 2 dogs treated with St and nobody of the CT group. Dogs seronegative at the end of the trial: 2/13 St; 0/14 CT. PCR: with both treatments negative and positive results alternated during and after therapy.
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/20.500.12317/20620
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact